Result page for
Withdrawn ID 837:
Amprenavir
General information:
Withdrawal information:
| Withdrawn due to drug safety reasons: | No |
| First approved: |
1999 |
| First withdrawn: |
2004 |
| Last withdrawn: |
2004 |
Side-effects:
| Total reported cases (submitted by medical professionals)
with Amprenavir as primary suspect: |
7 |
Reported final outcomes:
| Hospitalization (initial or prolonged): |
1 |
Reported side-effects:
| Side-effect |
Case number |
| LIPASE INCREASED | 1 |
| ACANTHOSIS NIGRICANS | 1 |
| ASTHENIA | 1 |
| BLOOD CHOLESTEROL INCREASED | 1 |
| CD4 LYMPHOCYTES DECREASED | 1 |
| DEPRESSION | 1 |
| HEPATOCELLULAR DAMAGE | 1 |
| HYPERGLYCAEMIA | 1 |
| INSOMNIA | 1 |
| INSULIN RESISTANCE | 1 |
| VIRAL LOAD INCREASED | 1 |
| LIPODYSTROPHY ACQUIRED | 1 |
| MUCOSAL ULCERATION | 1 |
| PARAESTHESIA CIRCUMORAL | 1 |
| PHARYNX DISCOMFORT | 1 |
| PRURITUS | 1 |
| RASH | 1 |
| RASH MACULO-PAPULAR | 1 |
| TOXIC SKIN ERUPTION | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID |
Activity in nm |
Target Name |
Target gene |
| P02545 |
631 |
Prelamin-A/C |
LMNA_HUMAN |
| P24557 |
6727 |
Thromboxane-A synthase |
THAS_HUMAN |
Toxicity information:
External links: